Get the Stockscreener App
0.92
2.23%
0.0201
After Hours:
.89
-0.03
-3.26%
Tscan Therapeutics Inc stock is traded at $0.92, with a volume of 447.77K.
It is up +2.23% in the last 24 hours and down -8.00% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.8999
Open:
$0.9112
24h Volume:
447.77K
Relative Volume:
0.56
Market Cap:
$60.12M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-0.961
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
-0.42%
1M Performance:
-8.00%
6M Performance:
-1.18%
1Y Performance:
-36.99%
1-Day Range:
$0.8721
$0.9332
1-Week Range:
$0.8481
$0.9962
52-Week Range:
$0.8481
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.92 | 60.12M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics (TCRX) Declines Sharply as Biotech Sector Headwinds IntensifySector Sentiment - newsline.com
Cellares and TScan to assess automated manufacturing of TSC-101 therapy - Yahoo Finance
Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate - Contract Pharma
Cellares, TScan to evaluate automated manufacturing for TSC-101 By Investing.com - Investing.com Australia
Cellares, TScan to evaluate automated manufacturing for TSC-101 - Investing.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Business Wire
TCRX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Advances Without RevenueFinancial Summary - newsline.com
TScan Therapeutics Cuts Net Loss to 28 Million Dollars - asatunews.co.id
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Insider Monkey
TScan Therapeutics hangs around $1.08; eyes on next week - Bez Kabli
TScan Therapeutics Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Growth Report - The Legal Advocate
TScan Therapeutics (TCRX) Rallies 3.9% as Shares Test Key Resistance LevelsPercent Below MA - The Legal Advocate
TScan Therapeutics Q1 2026 Earnings: Narrowing Loss Despite EPS Miss, Stock Gains on Pipeline ProgressConsensus Forecast Report - The Legal Advocate
TScan Therapeutics Expands Authorized Shares After Stockholder Vote - The Globe and Mail
TScan Therapeutics Analyst Ratings and Price Targets | NASDAQ:TCRX - Benzinga
TScan Therapeutics (TCRX) director granted stock options for 67,000 shares - Stock Titan
Baker-linked TScan (TCRX) director granted 67,000 stock options - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) wins vote to double authorized common stock - Stock Titan
TScan Therapeutics (TCRX) director awarded 67,000 stock options at $0.9946 - Stock Titan
Director at TScan Therapeutics (NASDAQ: TCRX) granted 67,000 options - Stock Titan
TScan Therapeutics (TCRX) director receives 67,000 stock option grant - Stock Titan
TScan Therapeutics (TCRX) director granted stock options on 67,000 shares - Stock Titan
TScan Therapeutics (TCRX) Stock Analysis: +3.27% Gain — What to Watch 2026-05-20Low Volatility Picks - Newser
TScan Therapeutics (TCRX) at $1.00 — Buy, Sell, or Hold? 2026-05-18Price Surge Stocks - The Legal Advocate
TScan Therapeutics, Inc.Common Stock (NQ: TCRX - FinancialContent
BVF group reports near‑10% stake in TScan Therapeutics (NASDAQ: TCRX) - Stock Titan
TradingKey - TradingKey
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
The fundamentals driving TScan Therapeutics (TCRX) everyone should understand (Under Pressure) 2026-05-08Institutional Buying - newser.com
Wedbush Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained - TipRanks
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Black Hills Pioneer
TScan Therapeutics Announces Q1 2026 Financial Results, Phase 3 TSC-101 Trial Launch, and Pipeline Updates - Minichart
TScan Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
TScan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics, Inc. 1Q 2026: Revenue $982K, EPS $(0.22) — 10-Q Summary - TradingView
TScan Therapeutics Reports $175.3 Million in Cash Reserves, Funding Operations Into Second Half of 2028 - geneonline.com
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):